Cannabis and CBD can increase antidepressant levels in adolescents through drug interactions
Pharmacokinetic modeling shows THC and CBD inhibit enzymes that metabolize common SSRIs, potentially increasing escitalopram and sertraline concentrations in adolescents, with CBD co-use linked to more side effects.
Quick Facts
What This Study Found
CBD and THC inhibit cytochrome enzymes (particularly CYP2C19) that metabolize SSRIs. PK models showed increased sertraline and escitalopram exposure in adolescents when co-administered with cannabinoids. FAERS data showed co-administration of CBD with CYP2C19-metabolized SSRIs increased the risk of cough, diarrhea, dizziness, and fatigue.
Key Numbers
Modeled interactions for escitalopram and sertraline with CBD and THC. FAERS analysis identified increased signals for cough, diarrhea, dizziness, and fatigue with CBD + CYP2C19-metabolized SSRIs.
How They Did This
Three-part approach: (1) review of cannabinoid-SSRI pharmacokinetic and pharmacodynamic interactions, (2) pediatric PK modeling of THC/CBD effects on escitalopram and sertraline exposure, and (3) analysis of FDA Adverse Events Reporting System (FAERS) data for CBD-SSRI side effect signals.
Why This Research Matters
With both cannabis use and antidepressant prescribing increasing among adolescents, clinicians need to understand how these substances interact to avoid unexpected increases in medication levels and side effects.
The Bigger Picture
Drug interactions between cannabinoids and psychiatric medications represent an underappreciated clinical concern, especially in adolescents who may not disclose cannabis use to prescribers.
What This Study Doesn't Tell Us
PK modeling rather than clinical measurement of actual drug levels. FAERS data is based on voluntary reporting and cannot confirm causation. Limited to two SSRIs.
Questions This Raises
- ?How significant are these interactions at typical recreational cannabis doses vs. therapeutic CBD doses?
- ?Should routine screening for cannabis use be standard before prescribing SSRIs to teens?
Trust & Context
- Key Stat:
- CBD co-use with SSRIs linked to increased dizziness, diarrhea, cough, and fatigue
- Evidence Grade:
- Combines PK modeling with adverse event database analysis, but lacks direct clinical measurement of drug levels in co-using patients.
- Study Age:
- Published in 2021.
- Original Title:
- The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations.
- Published In:
- Journal of personalized medicine, 11(7) (2021)
- Authors:
- Vaughn, Samuel E, Strawn, Jeffrey R(2), Poweleit, Ethan A, Sarangdhar, Mayur, Ramsey, Laura B
- Database ID:
- RTHC-03593
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How do cannabis and CBD affect antidepressant levels?
Both THC and CBD inhibit liver enzymes (especially CYP2C19) that break down SSRIs like escitalopram and sertraline, potentially causing higher-than-expected medication levels.
What side effects were seen when CBD was used with SSRIs?
FDA adverse event data showed increased reports of cough, diarrhea, dizziness, and fatigue when CBD was combined with CYP2C19-metabolized SSRIs.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- thc-and-ssris-cannabis-antidepressants
Cite This Study
https://rethinkthc.com/research/RTHC-03593APA
Vaughn, Samuel E; Strawn, Jeffrey R; Poweleit, Ethan A; Sarangdhar, Mayur; Ramsey, Laura B. (2021). The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations.. Journal of personalized medicine, 11(7). https://doi.org/10.3390/jpm11070615
MLA
Vaughn, Samuel E, et al. "The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations.." Journal of personalized medicine, 2021. https://doi.org/10.3390/jpm11070615
RethinkTHC
RethinkTHC Research Database. "The Impact of Marijuana on Antidepressant Treatment in Adole..." RTHC-03593. Retrieved from https://rethinkthc.com/research/vaughn-2021-the-impact-of-marijuana
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.